Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients

NCT07191171 · clinicaltrials.gov ↗
RECRUITING
Status
800
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

University Hospital, Strasbourg, France